Interrogating the transcriptome to find new cancer treatments
Our lab uses high-throughput sequencing data and experimental validations to find transcriptomic changes involved in normal tissue function or in cancer.
Current lines of investigation include:
- Target discovery for precision cancer immunotherapy
- Description of molecular mechanisms driving cancer
- Role of RNA splicing regulation during hematopoiesis
- Understanding gene sequence
News
01/2026 Nicolas joins the lab for his grad studies
11/2025 Juan and Tony win 2 out of 2 poster awards at the Department of Immunology and Cell
Biology Symposium
09/2025 Juan joins the lab for a 4-month COOP intership and Tony
returns for another intership
08/2025 Mikel joins the lab for his postdoctoral training
06/2025 Emma wins a RiboClub oral presentation award
05/2025 Nassima and Emma successfully transition to the Ph.D. program
05/2025 Léo is awarded an FMSS Excellence Scholarship
04/2025 The lab receives funding from NSERC to study splicing regulation during hematopoiesis
03/2025 Our project with Dr. Stéphanie Vairy is awarded a C17-Childhood Cancer Canada grant
for the development of personalized vaccines against childhood sarcoma
03/2025 Sarah joins the lab for a 5-month M1 internship
03/2025 Emma presents a poster at the D2R meeting
02/2025 Our collaborative project with Pr. Lee-Hwa Tai is awarded a CCS-Hecht Foundation
Disruptive Innovation Grant for the development of targeted immunotherapies against cholangiocarcinoma
01/2025 Tony joins the lab for a 4-month COOP internship
10/2024 Nassima and Emma present posters at the RiboClub meeting
09/2024 Léo joins the lab for his grad studies
08/2024 The lab receives a Startup Grant from D2R
04/2024 Mathieu is awarded a FRQS J1 career scholarship
Funding
The lab is supported by a Next Generation of Scientists Award from the Cancer Research Society, an Early career researchers competition in genomics – human health Award from Génome Québec, a Research Scholars Junior 1 scholarship from FRQS, a Canadian Cancer Society Disruptive Innovation Grant, a 100% sarcoma grant from C17/ Sarcoma Research Canada/Childhood Cancer Canada, a Discovery Grant from NSERC, as well as startup funds from the Université de Sherbrooke, CRCHUS and D2R.
